FDA
-
-
-
-
-
-
-
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
-
-
-
-
-
-
-
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
-
-
-
-
-
-
-
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
-
-
-
-
-
-
-
Vir Biotechnology (VIR) PT Raised to $15 at Morgan Stanley
-
-
-
-
-
-
-
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
-
-
-
-
-
-
-
Vir Biotechnology Inc. (VIR) Falls as FDA Says Sotrovimab no longer authorized to treat COVID-19 in any U.S. region
-
-
-
-
-
-
-
UPDATE: Vir Biotechnology Inc. (VIR) Falls to Low, FDA updates Sotrovimab emergency use authorization
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

